

SkinBioTherapeutics PLC

08:35 20 Nov 2019

Investor Update: SkinBio signs commercial deal with chemical giant Croda

Headlines from the Proactive UK newsroom.

SkinBioTherapeutics (LON:SBTX) has signed a commercial and manufacturing agreement for its Skinbiotix technology with speciality chemical giant Croda. It is the first major deal for the product with Croda to design and manufacture a new active skincare ingredient for its 12,000 cosmetic customers.

European Metals (LON:EMH) is to sell a majority stake in the Cinovec lithium project in the Czech Republic for €34mln. Local power utility CEZ is buying a 51% stake and will become the project's strategic partner.

Falcon Oil & Gas Ltd (LON:FOG, CVE:FO) has told investors that it's completed drilling the vertical section of the Kyalla 117 N2-1 appraisal well, in Australia's Beetaloo basin.

Integumen (LON:SKIN) says a project in Ireland to test reservoir water for E.coli returned results with almost 100% accuracy in a matter of seconds. The Rinocloud AI platform tested samples from a fully autonomous data buoy at Inniscarra in Cork.

Kingfisher (LON:KGF) saw sales fall again due to problems with new ranges, reduced promotional activity, ongoing problems in France and a weak UK market.

Foreign exchange specialist Argentex (LON:AGFX) boosted half year revenue by 42% in its first results since listing. Underlying profits more than doubled to £6.5mln as uncertainty surrounding the general election and Brexit encouraged a rush of new corporate clients.

Price: 12.5

Market Cap: £16.01 m

1 Year Share Price Graph



January 2019 July 2019 January 2020

Share Information

Code: SBTX

Listing: AIM

52 week High Low
26 12

Sector: Pharma & Biotech

Website: www.skinbiotherapeutics.com

Company Synopsis:

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to
Twenty Five Thousand dollars (\$25,000).